Literature DB >> 26645572

Do Pills Have No Ills? Capturing the Impact of Direct Treatment Disutility.

Alexander Thompson1, Bruce Guthrie2, Katherine Payne3.   

Abstract

Model-based economic evaluations should capture the impact on all costs and outcomes relevant to the chosen study perspective and time horizon. This editorial defines what is meant by direct treatment disutility (DTD) and describes why it could be an important harm that those designing model-based evaluations should consider. Some existing estimates of DTD identified from the current literature are summarised in terms of the methods used to elicit the values and the size of the estimated DTD. Model-based studies that include DTDs are also summarised. It was found that the values used within model-based economic evaluations (ranging from 0.00384 to 0.02) were typically smaller than the directly elicited values from the existing literature (0-0.033). Yet even with conservative estimates of DTDs, cost-effectiveness results were sensitive to their inclusion. The editorial concludes by discussing future methodological and empirical research needed to estimate more robust DTD values.

Entities:  

Mesh:

Year:  2016        PMID: 26645572     DOI: 10.1007/s40273-015-0357-9

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  17 in total

1.  Process utility from providing informal care: the benefit of caring.

Authors:  Werner B F Brouwer; N Job A van Exel; Bernard van den Berg; Geertruidis A M van den Bos; Marc A Koopmanschap
Journal:  Health Policy       Date:  2005-01-08       Impact factor: 2.980

Review 2.  Incorporating process utility into quality adjusted life years: a systematic review of empirical studies.

Authors:  Victoria K Brennan; Simon Dixon
Journal:  Pharmacoeconomics       Date:  2013-08       Impact factor: 4.981

3.  Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis.

Authors:  Mark J Pletcher; Michael Pignone; Stephanie Earnshaw; Cheryl McDade; Kathryn A Phillips; Reto Auer; Lydia Zablotska; Philip Greenland
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-03-11

4.  Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.

Authors:  J P Greving; F L J Visseren; G A de Wit; A Algra
Journal:  BMJ       Date:  2011-03-30

5.  Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.

Authors:  Mark J Pletcher; Lawrence Lazar; Kirsten Bibbins-Domingo; Andrew Moran; Nicolas Rodondi; Pamela Coxson; James Lightwood; Lawrence Williams; Lee Goldman
Journal:  Ann Intern Med       Date:  2009-02-17       Impact factor: 25.391

6.  Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.

Authors:  Michael Pignone; Stephanie Earnshaw; Jeffrey A Tice; Mark J Pletcher
Journal:  Ann Intern Med       Date:  2006-03-07       Impact factor: 25.391

7.  Whither trial-based economic evaluation for health care decision making?

Authors:  Mark J Sculpher; Karl Claxton; Mike Drummond; Chris McCabe
Journal:  Health Econ       Date:  2006-07       Impact factor: 3.046

8.  Quantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey.

Authors:  Robert Hutchins; Michael P Pignone; Stacey L Sheridan; Anthony J Viera
Journal:  BMJ Open       Date:  2015-05-11       Impact factor: 2.692

9.  Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Eric T Roberts; Aaron Horne; Seth S Martin; Michael J Blaha; Ron Blankstein; Matthew J Budoff; Christopher Sibley; Joseph F Polak; Kevin D Frick; Roger S Blumenthal; Khurram Nasir
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

10.  Patient-accessible tool for shared decision making in cardiovascular primary prevention: balancing longevity benefits against medication disutility.

Authors:  Marianna Fontana; Perviz Asaria; Michela Moraldo; Judith Finegold; Khalil Hassanally; Charlotte H Manisty; Darrel P Francis
Journal:  Circulation       Date:  2014-04-17       Impact factor: 29.690

View more
  3 in total

1.  Priorities among effective clinical preventive services in British Columbia, Canada.

Authors:  Hans Krueger; Sylvia Robinson; Trevor Hancock; Richard Birtwhistle; Jane A Buxton; Bonnie Henry; Jennifer Scarr; John J Spinelli
Journal:  BMC Health Serv Res       Date:  2022-04-26       Impact factor: 2.908

2.  Using the Payoff Time in Decision-Analytic Models: A Case Study for Using Statins in Primary Prevention.

Authors:  Alexander Thompson; Bruce Guthrie; Katherine Payne
Journal:  Med Decis Making       Date:  2017-04-25       Impact factor: 2.583

3.  Predictive performance of a competing risk cardiovascular prediction tool CRISK compared to QRISK3 in older people and those with comorbidity: population cohort study.

Authors:  Shona J Livingstone; Bruce Guthrie; Peter T Donnan; Alexander Thompson; Daniel R Morales
Journal:  BMC Med       Date:  2022-05-04       Impact factor: 11.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.